List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4785644/publications.pdf Version: 2024-02-01

		38742	49909
171	10,217	50	87
papers	citations	h-index	g-index
212	212	212	10796
all docs	docs citations	times ranked	citing authors

ΔνηρÃ@ς Είνιζι

#	Article	IF	CITATIONS
1	Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01. Science, 2010, 329, 811-817.	12.6	1,050
2	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	12.6	468
3	Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. Journal of Virology, 2014, 88, 2633-2644.	3.4	237
4	Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 5663-5668.	7.1	222
5	Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nature Medicine, 2021, 27, 2012-2024.	30.7	206
6	Cross-Sectional Evaluation of Humoral Responses against SARS-CoV-2 Spike. Cell Reports Medicine, 2020, 1, 100126.	6.5	200
7	Topological Layers in the HIV-1 gp120 Inner Domain Regulate gp41 Interaction and CD4-Triggered Conformational Transitions. Molecular Cell, 2010, 37, 656-667.	9.7	194
8	Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals. MBio, 2020, 11, .	4.1	186
9	HIV-1 Vpr-Mediated G2 Arrest Involves the DDB1-CUL4AVPRBP E3 Ubiquitin Ligase. PLoS Pathogens, 2007, 3, e85.	4.7	175
10	The HIV-1 gp120 CD4-Bound Conformation Is Preferentially Targeted by Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Sera from HIV-1-Infected Individuals. Journal of Virology, 2015, 89, 545-551.	3.4	173
11	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. Cell Host and Microbe, 2021, 29, 1137-1150.e6.	11.0	173
12	Single-Cell Characterization of Viral Translation-Competent Reservoirs in HIV-Infected Individuals. Cell Host and Microbe, 2016, 20, 368-380.	11.0	170
13	Associating HIV-1 envelope glycoprotein structures with states on theÂvirus observed by smFRET. Nature, 2019, 568, 415-419.	27.8	156
14	Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy. Immunity, 2021, 54, 2143-2158.e15.	14.3	155
15	Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction. Cell Host and Microbe, 2016, 20, 429-442.	11.0	154
16	Vaccine-Induced Protection from Homologous Tier 2 SHIV Challenge in Nonhuman Primates Depends on Serum-Neutralizing Antibody Titers. Immunity, 2019, 50, 241-252.e6.	14.3	153
17	Real-Time Conformational Dynamics of SARS-CoV-2 Spikes on Virus Particles. Cell Host and Microbe, 2020, 28, 880-891.e8.	11.0	153
18	A B-Box 2 Surface Patch Important for TRIM5α Self-Association, Capsid Binding Avidity, and Retrovirus Restriction. Journal of Virology, 2009, 83, 10737-10751.	3.4	145

#	Article	IF	CITATIONS
19	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8Âmonths post-symptom onset. Cell Reports Medicine, 2021, 2, 100290.	6.5	145
20	Macrophage Infection via Selective Capture of HIV-1-Infected CD4+ T Cells. Cell Host and Microbe, 2014, 16, 711-721.	11.0	143
21	Release of gp120 Restraints Leads to an Entry-Competent Intermediate State of the HIV-1 Envelope Glycoproteins. MBio, 2016, 7, .	4.1	131
22	Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset. Blood, 2020, 136, 2588-2591.	1.4	127
23	CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E2687-94.	7.1	118
24	Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nature Chemical Biology, 2017, 13, 1115-1122.	8.0	110
25	Molecular architecture of the uncleaved HIV-1 envelope glycoprotein trimer. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12438-12443.	7.1	101
26	Productive Human Immunodeficiency Virus Type 1 Assembly Takes Place at the Plasma Membrane. Journal of Virology, 2007, 81, 7476-7490.	3.4	97
27	Structural basis and mode of action for two broadly neutralizing antibodies against SARS-CoV-2 emerging variants of concern. Cell Reports, 2022, 38, 110210.	6.4	96
28	Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. Cell Reports, 2021, 36, 109353.	6.4	95
29	Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2. Cell Reports, 2021, 34, 108790.	6.4	94
30	An Asymmetric Opening of HIV-1 Envelope Mediates Antibody-Dependent Cellular Cytotoxicity. Cell Host and Microbe, 2019, 25, 578-587.e5.	11.0	93
31	Altered differentiation is central to HIV-specific CD4+ T cell dysfunction in progressive disease. Nature Immunology, 2019, 20, 1059-1070.	14.5	84
32	Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Host and Microbe, 2022, 30, 97-109.e5.	11.0	83
33	Uninfected Bystander Cells Impact the Measurement of HIV-Specific Antibody-Dependent Cellular Cytotoxicity Responses. MBio, 2018, 9, .	4.1	82
34	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection. Cell Reports, 2022, 38, 110368.	6.4	82
35	Effect of HIV-1 Env on SERINC5 Antagonism. Journal of Virology, 2017, 91, .	3.4	81
36	A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques. Nature Medicine, 2021, 27, 2234-2245.	30.7	80

#	Article	IF	CITATIONS
37	The great escape? SARS-CoV-2 variants evading neutralizing responses. Cell Host and Microbe, 2021, 29, 322-324.	11.0	78
38	A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nature Chemical Biology, 2014, 10, 845-852.	8.0	77
39	Contribution of single mutations to selected SARS-CoV-2 emerging variants spike antigenicity. Virology, 2021, 563, 134-145.	2.4	74
40	Nef Proteins from HIV-1 Elite Controllers Are Inefficient at Preventing Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2016, 90, 2993-3002.	3.4	72
41	Role of CD4 Receptor Down-regulation During HIV-1 Infection. Current HIV Research, 2004, 2, 51-59.	0.5	71
42	A Highly Conserved Residue of the HIV-1 gp120 Inner Domain Is Important for Antibody-Dependent Cellular Cytotoxicity Responses Mediated by Anti-cluster A Antibodies. Journal of Virology, 2016, 90, 2127-2134.	3.4	69
43	Small CD4 Mimetics Prevent HIV-1 Uninfected Bystander CD4 + T Cell Killing Mediated by Antibody-dependent Cell-mediated Cytotoxicity. EBioMedicine, 2016, 3, 122-134.	6.1	67
44	Antibody-dependent cellular cytotoxicity in HIV infection. Aids, 2018, 32, 2439-2451.	2.2	67
45	Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses. Cell Host and Microbe, 2015, 18, 354-362.	11.0	66
46	The Conformational States of the HIV-1 Envelope Glycoproteins. Trends in Microbiology, 2020, 28, 655-667.	7.7	66
47	Co-receptor Binding Site Antibodies Enable CD4-Mimetics to Expose Conserved Anti-cluster A ADCC Epitopes on HIV-1 Envelope Glycoproteins. EBioMedicine, 2016, 12, 208-218.	6.1	65
48	A V3 Loop-Dependent gp120 Element Disrupted by CD4 Binding Stabilizes the Human Immunodeficiency Virus Envelope Glycoprotein Trimer. Journal of Virology, 2010, 84, 3147-3161.	3.4	64
49	Impact of HIV-1 Envelope Conformation on ADCC Responses. Trends in Microbiology, 2018, 26, 253-265.	7.7	64
50	Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. Journal of Virological Methods, 2014, 208, 107-114.	2.1	62
51	Transitions to and from the CD4-Bound Conformation Are Modulated by a Single-Residue Change in the Human Immunodeficiency Virus Type 1 gp120 Inner Domain. Journal of Virology, 2009, 83, 8364-8378.	3.4	57
52	Incomplete Downregulation of CD4 Expression Affects HIV-1 Env Conformation and Antibody-Dependent Cellular Cytotoxicity Responses. Journal of Virology, 2018, 92, .	3.4	56
53	Multiparametric characterization of rare HIV-infected cells using an RNA-flow FISH technique. Nature Protocols, 2017, 12, 2029-2049.	12.0	55
54	Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1-Infected Cells. Journal of Virology, 2016, 90, 2021-2030.	3.4	53

#	Article	IF	CITATIONS
55	Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors. Journal of Virology, 2017, 91, .	3.4	53
56	Effects of the I559P gp41 Change on the Conformation and Function of the Human Immunodeficiency Virus (HIV-1) Membrane Envelope Glycoprotein Trimer. PLoS ONE, 2015, 10, e0122111.	2.5	52
57	Influence of the Envelope gp120 Phe 43 Cavity on HIV-1 Sensitivity to Antibody-Dependent Cell-Mediated Cytotoxicity Responses. Journal of Virology, 2017, 91, .	3.4	52
58	Identification of a Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Variant Resistant to Cold Inactivation. Journal of Virology, 2009, 83, 4476-4488.	3.4	50
59	Immune Checkpoint Blockade Restores HIV-Specific CD4 T Cell Help for NK Cells. Journal of Immunology, 2018, 201, 971-981.	0.8	50
60	SARS-CoV-2 Omicron Spike recognition by plasma from individuals receiving BNT162b2 mRNA vaccination with a 16-week interval between doses. Cell Reports, 2022, 38, 110429.	6.4	50
61	The Highly Conserved Layer-3 Component of the HIV-1 gp120 Inner Domain Is Critical for CD4-Required Conformational Transitions. Journal of Virology, 2013, 87, 2549-2562.	3.4	49
62	SARS-CoV-2 Variants Increase Kinetic Stability of Open Spike Conformations as an Evolutionary Strategy. MBio, 2022, 13, e0322721.	4.1	48
63	Covid-19 vaccine immunogenicity in people living with HIV-1. Vaccine, 2022, 40, 3633-3637.	3.8	47
64	Paring Down HIV Env: Design and Crystal Structure of a Stabilized Inner Domain of HIV-1 gp120 Displaying a Major ADCC Target of the A32 Region. Structure, 2016, 24, 697-709.	3.3	46
65	A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge. Nature Communications, 2018, 9, 2363.	12.8	46
66	Two Families of Env Antibodies Efficiently Engage Fc-Gamma Receptors and Eliminate HIV-1-Infected Cells. Journal of Virology, 2019, 93, .	3.4	44
67	Conformational Masking and Receptor-Dependent Unmasking of Highly Conserved Env Epitopes Recognized by Non-Neutralizing Antibodies That Mediate Potent ADCC against HIV-1. Viruses, 2015, 7, 5115-5132.	3.3	42
68	Slaying the Trojan Horse: Natural Killer Cells Exhibit Robust Anti-HIV-1 Antibody-Dependent Activation and Cytolysis against Allogeneic T Cells. Journal of Virology, 2015, 89, 97-109.	3.4	42
69	Persistent expansion and Th1-like skewing of HIV-specific circulating T follicular helper cells during antiretroviral therapy. EBioMedicine, 2020, 54, 102727.	6.1	42
70	Impact of temperature on the affinity of SARS-CoV-2 Spike glycoprotein for host ACE2. Journal of Biological Chemistry, 2021, 297, 101151.	3.4	42
71	Role of HIV-1 Envelope Glycoproteins Conformation and Accessory Proteins on ADCC Responses. Current HIV Research, 2015, 14, 9-23.	0.5	42
72	Species-Specific Inhibition of Foamy Viruses from South American Monkeys by New World Monkey TRIM5α Proteins. Journal of Virology, 2010, 84, 4095-4099.	3.4	41

#	Article	IF	CITATIONS
73	BST-2 Expression Modulates Small CD4-Mimetic Sensitization of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2017, 91, .	3.4	40
74	Comparison of Uncleaved and Mature Human Immunodeficiency Virus Membrane Envelope Glycoprotein Trimers. Journal of Virology, 2018, 92, .	3.4	40
75	Envelope glycoproteins sampling states 2/3 are susceptible to ADCC by sera from HIV-1-infected individuals. Virology, 2018, 515, 38-45.	2.4	40
76	Short-term antibody response after 1 dose of BNT162b2 vaccine in patients receiving hemodialysis. Cmaj, 2021, 193, E793-E800.	2.0	40
77	The V3 Loop of HIV-1 Env Determines Viral Susceptibility to IFITM3 Impairment of Viral Infectivity. Journal of Virology, 2017, 91, .	3.4	37
78	The HIV-1 Env gp120 Inner Domain Shapes the Phe43 Cavity and the CD4 Binding Site. MBio, 2020, 11, .	4.1	37
79	Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay. Journal of Visualized Experiments, 2014, , 51995.	0.3	36
80	Beyond Viral Neutralization. AIDS Research and Human Retroviruses, 2017, 33, 760-764.	1.1	36
81	Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. Journal of Virological Methods, 2010, 168, 155-161.	2.1	35
82	Identification of HIV gp41-specific antibodies that mediate killing of infected cells. PLoS Pathogens, 2019, 15, e1007572.	4.7	35
83	Evaluation of a Commercial Culture-Free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison With an Antireceptor-Binding Domain Enzyme-Linked Immunosorbent Assay. Open Forum Infectious Diseases, 2021, 8, ofab220.	0.9	33
84	Antibody-Induced Internalization of HIV-1 Env Proteins Limits Surface Expression of the Closed Conformation of Env. Journal of Virology, 2019, 93, .	3.4	32
85	An Inducible Cell-Cell Fusion System with Integrated Ability to Measure the Efficiency and Specificity of HIV-1 Entry Inhibitors. PLoS ONE, 2011, 6, e26731.	2.5	32
86	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality. Science Advances, 2021, 7, eabj5629.	10.3	32
87	NKG2D Acts as a Co-Receptor for Natural Killer Cell-Mediated Anti-HIV-1 Antibody-Dependent Cellular Cytotoxicity. AIDS Research and Human Retroviruses, 2016, 32, 1089-1096.	1.1	31
88	Molecular basis for epitope recognition by non-neutralizing anti-gp41 antibody F240. Scientific Reports, 2016, 6, 36685.	3.3	31
89	Targeting the Late Stage of HIV-1 Entry for Antibody-Dependent Cellular Cytotoxicity: Structural Basis for Env Epitopes in the C11 Region. Structure, 2017, 25, 1719-1731.e4.	3.3	31
90	Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5α. Virology, 2010, 408, 204-212.	2.4	30

#	Article	IF	CITATIONS
91	Lineage-Specific Differences between Human and Simian Immunodeficiency Virus Regulation of gp120 Trimer Association and CD4 Binding. Journal of Virology, 2012, 86, 8974-8986.	3.4	30
92	Impaired Downregulation of NKG2D Ligands by Nef Proteins from Elite Controllers Sensitizes HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2017, 91, .	3.4	30
93	CD4 Incorporation into HIV-1 Viral Particles Exposes Envelope Epitopes Recognized by CD4-Induced Antibodies. Journal of Virology, 2019, 93, .	3.4	29
94	Interaction of Human ACE2 to Membrane-Bound SARS-CoV-1 and SARS-CoV-2 S Glycoproteins. Viruses, 2020, 12, 1104.	3.3	29
95	Modulating HIV-1 envelope glycoprotein conformation to decrease the HIV-1 reservoir. Cell Host and Microbe, 2021, 29, 904-916.e6.	11.0	29
96	HIV-1 Vpu Downregulates Tim-3 from the Surface of Infected CD4 <sup>+</sup> T Cells. Journal of Virology, 2020, 94, .	3.4	28
97	A new flow cytometry assay to measure antibody-dependent cellular cytotoxicity against SARS-CoV-2 Spike-expressing cells. STAR Protocols, 2021, 2, 100851.	1.2	28
98	Major Histocompatibility Complex Class II Molecules Promote Human Immunodeficiency Virus Type 1 Assembly and Budding to Late Endosomal/Multivesicular Body Compartments. Journal of Virology, 2006, 80, 9789-9797.	3.4	27
99	Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. Science Advances, 2022, 8, .	10.3	27
100	Short Communication: Small-Molecule CD4 Mimetics Sensitize HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity by Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Nonhuman Primates. AIDS Research and Human Retroviruses, 2017, 33, 428-431.	1.1	26
101	A New Family of Small-Molecule CD4-Mimetic Compounds Contacts Highly Conserved Aspartic Acid 368 of HIV-1 gp120 and Mediates Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2019, 93, .	3.4	26
102	Antibody Binding to SARS-CoV-2 S Glycoprotein Correlates with but Does Not Predict Neutralization. Viruses, 2020, 12, 1214.	3.3	26
103	Multicenter Evaluation of the Clinical Performance and the Neutralizing Antibody Activity Prediction Properties of 10 High-Throughput Serological Assays Used in Clinical Laboratories. Journal of Clinical Microbiology, 2021, 59, .	3.9	25
104	Short Communication: Anti-HIV-1 Envelope Immunoglobulin Gs in Blood and Cervicovaginal Samples of Beninese Commercial Sex Workers. AIDS Research and Human Retroviruses, 2014, 30, 1145-1149.	1.1	24
105	SOSIP Changes Affect Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Conformation and CD4 Engagement. Journal of Virology, 2018, 92, .	3.4	24
106	Identification of SARS-CoV-2–specific immune alterations in acutely ill patients. Journal of Clinical Investigation, 2021, 131, .	8.2	24
107	Histidine 375 Modulates CD4 Binding in HIV-1 CRF01_AE Envelope Glycoproteins. Journal of Virology, 2017, 91, .	3.4	23
108	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. Cell Host and Microbe, 2020, 27, 963-975.e5.	11.0	23

#	ARTICLE	IF	CITATIONS
109	Virus-Specific Effects of TRIM5Ârh RING Domain Functions on Restriction of Retroviruses. Journal of Virology, 2013, 87, 7234-7245.	3.4	21
110	HIV-1 gp120 dimers decrease the overall affinity of gp120 preparations for CD4-induced ligands. Journal of Virological Methods, 2015, 215-216, 37-44.	2.1	21
111	First Phase I human clinical trial of a killed whole-HIV-1 vaccine: demonstration of its safety and enhancement of anti-HIV antibody responses. Retrovirology, 2016, 13, 82.	2.0	21
112	CD4 receptor diversity in chimpanzees protects against SIV infection. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3229-3238.	7.1	21
113	The HIV-1 gp120 Major Variable Regions Modulate Cold Inactivation. Journal of Virology, 2013, 87, 4103-4111.	3.4	20
114	Defining rules governing recognition and Fc-mediated effector functions to the HIV-1 co-receptor binding site. BMC Biology, 2020, 18, 91.	3.8	20
115	Two-step purification of His-tagged Nef protein in native condition using heparin and immobilized metal ion affinity chromatographies. Journal of Virological Methods, 2003, 111, 69-73.	2.1	19
116	Adoption of an "Open―Envelope Conformation Facilitating CD4 Binding and Structural Remodeling Precedes Coreceptor Switch in R5 SHIV-Infected Macaques. PLoS ONE, 2011, 6, e21350.	2.5	18
117	5′ Rapid Amplification of cDNA Ends and Illumina MiSeq Reveals B Cell Receptor Features in Healthy Adults, Adults With Chronic HIV-1 Infection, Cord Blood, and Humanized Mice. Frontiers in Immunology, 2018, 9, 628.	4.8	18
118	Natural HIV-1 Nef Polymorphisms Impair SERINC5 Downregulation Activity. Cell Reports, 2019, 29, 1449-1457.e5.	6.4	18
119	SARS-CoV-2 seroprevalence among blood donors in Québec, and analysis of symptoms associated with seropositivity: a nested case-control study. Canadian Journal of Public Health, 2021, 112, 576-586.	2.3	18
120	Novel Acylguanidine-Based Inhibitor of HIV-1. Journal of Virology, 2016, 90, 9495-9508.	3.4	17
121	Antibody-Dependent Cellular Cytotoxicity-Competent Antibodies against HIV-1-Infected Cells in Plasma from HIV-Infected Subjects. MBio, 2019, 10, .	4.1	17
122	Highâ€ŧhroughput detection of antibodies targeting the <scp>SARSâ€CoV</scp> â€⊋ <scp>Spike</scp> in longitudinal convalescent plasma samples. Transfusion, 2021, 61, 1377-1382.	1.6	17
123	Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays. Microbiology Spectrum, 2021, 9, e0088621.	3.0	17
124	Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection. Viruses, 2022, 14, 532.	3.3	17
125	Upregulation of BST-2 by Type I Interferons Reduces the Capacity of Vpu To Protect HIV-1-Infected Cells from NK Cell Responses. MBio, 2019, 10, .	4.1	16
126	SARS-CoV-2 Spike Expression at the Surface of Infected Primary Human Airway Epithelial Cells. Viruses, 2022, 14, 5.	3.3	16

#	Article	IF	CITATIONS
127	A Highly Conserved gp120 Inner Domain Residue Modulates Env Conformation and Trimer Stability. Journal of Virology, 2016, 90, 8395-8409.	3.4	15
128	HIV-1 gp120 envelope glycoprotein determinants for cytokine burst in human monocytes. PLoS ONE, 2017, 12, e0174550.	2.5	15
129	Understudied Factors Influencing Fc-Mediated Immune Responses against Viral Infections. Vaccines, 2019, 7, 103.	4.4	15
130	Opening the HIV envelope: potential of CD4 mimics as multifunctional HIV entry inhibitors. Current Opinion in HIV and AIDS, 2020, 15, 300-308.	3.8	15
131	Immune Correlates of Disease Progression in Linked HIV-1 Infection. Frontiers in Immunology, 2019, 10, 1062.	4.8	14
132	A Highly Conserved Residue in HIV-1 Nef Alpha Helix 2 Modulates Protein Expression. MSphere, 2016, 1, .	2.9	12
133	Pharmacological Inhibition of PPAR <sub>y</sub> Boosts HIV Reactivation and Th17 Effector Functions, while Preventing Progeny Virion Release and <i>de novo</i> Infection. Pathogens and Immunity, 2020, 5, 177.	3.1	12
134	Antigenicity of the Mu (B.1.621) and A.2.5 SARS-CoV-2 Spikes. Viruses, 2022, 14, 144.	3.3	12
135	Contribution of the gp120 V3 loop to envelope glycoprotein trimer stability in primate immunodeficiency viruses. Virology, 2018, 521, 158-168.	2.4	11
136	CD4- and Time-Dependent Susceptibility of HIV-1-Infected Cells to Antibody-Dependent Cellular Cytotoxicity. Journal of Virology, 2019, 93, .	3.4	11
137	Differential Pressures of SERINC5 and IFITM3 on HIV-1 Envelope Glycoprotein over the Course of HIV-1 Infection. Journal of Virology, 2020, 94, .	3.4	11
138	The HIV-1 accessory protein Nef increases surface expression of the checkpoint receptor Tim-3 in infected CD4+ T cells. Journal of Biological Chemistry, 2021, 297, 101042.	3.4	11
139	B-cell cytopenia and time to last B-cell-depleting therapy predict response to SARS-COV-2 vaccines in patients with lymphoproliferative disorders. Vaccine, 2022, 40, 1203-1207.	3.8	11
140	Detection of the HIV-1 Accessory Proteins Nef and Vpu by Flow Cytometry Represents a New Tool to Study Their Functional Interplay within a Single Infected CD4 <sup>+</sup> T Cell. Journal of Virology, 2022, 96, jvi0192921.	3.4	10
141	SARS-CoV-2 Accessory Protein ORF8 Decreases Antibody-Dependent Cellular Cytotoxicity. Viruses, 2022, 14, 1237.	3.3	10
142	Effects of the SOS (A501C/T605C) and DS (I201C/A433C) Disulfide Bonds on HIV-1 Membrane Envelope Glycoprotein Conformation and Function. Journal of Virology, 2019, 93, .	3.4	9
143	Stabilizing the HIV-1 Envelope Glycoprotein State 2A Conformation. Journal of Virology, 2021, 95, .	3.4	9
144	Identification of interdependent variables that influence coreceptor switch in R5 SHIVSF162P3N-infected macaques. Retrovirology, 2012, 9, 106.	2.0	8

#	Article	IF	CITATIONS
145	Unlocking HIV-1 Env: implications for antibody attack. AIDS Research and Therapy, 2017, 14, 42.	1.7	8
146	Optimization of Small Molecules That Sensitize HIV-1 Infected Cells to Antibody-Dependent Cellular Cytotoxicity. ACS Medicinal Chemistry Letters, 2020, 11, 371-378.	2.8	8
147	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. PLoS Pathogens, 2022, 18, e1010183.	4.7	8
148	VE607 stabilizes SARS-CoV-2 Spike in the "RBD-up―conformation and inhibits viral entry. IScience, 2022, 25, 104528.	4.1	8
149	Elicitation of Cluster A and Co-Receptor Binding Site Antibodies Are Required to Eliminate HIV-1 Infected Cells. Microorganisms, 2020, 8, 710.	3.6	7
150	Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. SSRN Electronic Journal, 0, , .	0.4	7
151	Lineage-Specific Differences between the gp120 Inner Domain Layer 3 of Human Immunodeficiency Virus and That of Simian Immunodeficiency Virus. Journal of Virology, 2016, 90, 10065-10073.	3.4	6
152	Enhanced Ability of Plant-Derived PGT121 Glycovariants To Eliminate HIV-1-Infected Cells. Journal of Virology, 2021, 95, e0079621.	3.4	6
153	Major histocompatibility complex class-II molecules promote targeting of human immunodeficiency virus type 1 virions in late endosomes by enhancing internalization of nascent particles from the plasma membrane. Cellular Microbiology, 2013, 15, 809-822.	2.1	5
154	Incorporating the Cluster A and V1V2 Targets into a Minimal Structural Unit of the HIV-1 Envelope to Elicit a Cross-Clade Response with Potent Fc-Effector Functions. Vaccines, 2021, 9, 975.	4.4	5
155	Temsavir Treatment of HIV-1-Infected Cells Decreases Envelope Glycoprotein Recognition by Broadly Neutralizing Antibodies. MBio, 2022, 13, e0057722.	4.1	5
156	The HIV Latency Reversal Agent HODHBt Enhances NK Cell Effector and Memory-Like Functions by Increasing Interleukin-15-Mediated STAT Activation. Journal of Virology, 2022, 96, .	3.4	5
157	HIV-1 Adapts To Replicate in Cells Expressing Common Marmoset APOBEC3G and BST2. Journal of Virology, 2016, 90, 725-740.	3.4	4
158	Blocking HIV-1 replication: are Fc–Fcγ receptor interactions required?. Journal of Clinical Investigation, 2018, 129, 53-54.	8.2	4
159	Across Functional Boundaries: Making Nonneutralizing Antibodies To Neutralize HIV-1 and Mediate Fc-Mediated Effector Killing of Infected Cells. MBio, 2021, 12, e0140521.	4.1	3
160	Exposing HIV-1 Env: Implications for therapeutic strategies. Clinical and Investigative Medicine, 2019, 42, E2-E6.	0.6	3
161	Seroprevalence of SARS-CoV-2 antibodies among blood donors in Québec: an update from a serial cross-sectional study. Canadian Journal of Public Health, 2022, 113, 385-393.	2.3	3
162	Soluble Envelope Glycoprotein Trimers from a CD4-Independent HIV-1 Elicit Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies in Guinea Pigs. Journal of Virology, 2015, 89, 10707-10711.	3.4	2

#	Article	IF	CITATIONS
163	Uncovering HIV-1-infected cells. Oncotarget, 2015, 6, 21791-21792.	1.8	2
164	HIV-1 Envelope Glycoprotein Cell Surface Localization Is Associated with Antibody-Induced Internalization. Viruses, 2021, 13, 1953.	3.3	2
165	HIV-1 Envelope Clycoproteins Proteolytic Cleavage Protects Infected Cells from ADCC Mediated by Plasma from Infected Individuals. Viruses, 2021, 13, 2236.	3.3	2
166	Novel Compound Inhibitors of HIV-1NL4-3 Vpu. Viruses, 2022, 14, 817.	3.3	2
167	Effects of gp120 Inner Domain (ID2) Immunogen Doses on Elicitation of Anti-HIV-1 Functional Fc-Effector Response to C1/C2 (Cluster A) Epitopes in Mice. Microorganisms, 2020, 8, 1490.	3.6	1
168	HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance. , 2017, , 545-557.		1
169	Standardization of a flow cytometry SARS-CoV-2 serologic test. Cytotechnology, 2022, 74, 99-103.	1.6	1
170	Enhancement of CD4 Binding, Host Cell Entry, and Sensitivity to CD4bs Antibody Inhibition Conferred by a Natural but Rare Polymorphism in the HIV-1 Envelope. Journal of Virology, 2022, 96, .	3.4	1
171	Editorial: Exploring Novel Approaches to Eliminate HIV Reservoirs to Achieve a Cure for HIV. Frontiers in Cellular and Infection Microbiology, 2021, 11, 658848.	3.9	ο